NIH Funding Opportunity Focuses on Diagnostics for Hospital-Based Antibacterial-Resistant Infections

Awards to Total up to $12 Million in 2015
April 7, 2014
​The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, recently announced a research funding opportunity to develop and/or produce diagnostics to quickly detect the key bacteria responsible for antibacterial-resistant infections in hospital settings. NIAID expects to fund 10-15 awards for a total of up to $12 million in 2015. The maximum length of each award is 5 years.
 
Drug-resistant bacterial infections are a growing worldwide problem, causing significant illness, death and healthcare cost. Many of these infections are acquired in hospitals and other healthcare settings, where rapid and sensitive testing for specific types of bacteria are needed to enable physicians to determine the most effective treatments to improve individual patient outcomes and help curb bacterial resistance.
 
The new request for applications (RFA), called "Partnerships for Diagnostics to Address Antimicrobial Resistance of Select Bacterial Pathogens," will support diagnostics research related to one or more of the following five types of bacteria commonly responsible for antibacterial-resistant infections in hospitals: Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, and extra-intestinal pathogenic Eschericihia coli.
 
Investigators from academic organizations are eligible to submit proposals, but must establish a partnership with an industrial organization. Applications submitted by industrial institutions or non-profit product development agencies do not require an additional partner.
 
NIAID will accept applications through June 19, 2014. View the complete RFA (RFA-AI-14-019).
Content last reviewed on April 7, 2014